PRADAXA safely and effectively. See full prescribing information for. PRADAXA. PRADAXA® (dabigatran etexilate mesylate) capsules, for oral use. Initial U.S. produce dabigatran exposure similar to that observed in severe renal impairment . Consider reducing the dose of PRADAXA to 75 mg twice daily [see Drug. This is a summary of the European public assessment report (EPAR) for Pradaxa. It explains how the Committee for Medicinal Products for Human Use (CHMP).
|Published (Last):||3 February 2006|
|PDF File Size:||14.74 Mb|
|ePub File Size:||6.18 Mb|
|Price:||Free* [*Free Regsitration Required]|
Risk factors Table 2 summarises factors which may increase the haemorrhagic risk. Tell your doctor right away if you have back pain, tingling, numbness, dablgatran weakness especially in your legs and feetloss of control of the bowels or bladder incontinence. Marketing authorisation number s 9.
Pradaxa 150 mg hard capsules
A coagulation test see section 4. Clinical trials in Venous Thromboembolism VTE prophylaxis following major joint replacement surgery In 2 large randomized, eabigatran group, double-blind, dose-confirmatory trials, patients undergoing elective major orthopaedic surgery one for knee replacement surgery and one for hip replacement surgery received Pradaxa 75 mg or mg within hours of zpc followed by mg or mg daily thereafter, haemostasis having been secured, or enoxaparin 40 mg on the day prior to surgery and daily thereafter.
Tell your doctor if you are breastfeeding or plan to breastfeed. Patients on Pradaxa sspc undergo surgery or invasive procedures are at increased risk for bleeding. Arthroplasty, Replacement Venous Thromboembolism. The ECT can provide a direct measure of the activity of direct thrombin inhibitors. In patients treated for prevention of VTEs after hip or knee replacement surgery with mg dabigatran etexilate once daily.
View all 4 ratings.
Particular caution should be exercised when Pradaxa is co-administered with verapamil, amiodarone, quinidine or clarithromycin P-gp inhibitors and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment see section 4. Treatment initiation on the day of surgery hours after completed surgery.
In clinical trials, Pradaxa was associated with higher rates of major gastrointestinal GI bleeding. This is explained by completed dabigatran absorption after 2 hours.
Choose Pradaxa® (dabigatran etexilate) for AFib, DVT or PE
Concomitant administration of a loading dose of mg ticagrelor and mg dabigatran etexilate in steady state increased the dabigatran AUC ,ss and C max,ss by 1. Number of patients treated with Pradaxa. In general, it can be assumed that these measures of anti-coagulant activity may reflect dabigatran levels and can provide guidance for the assessment of bleeding risk, i. Injury, poisoning and procedural complications. Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, dzbigatran dose toxicity and genotoxicity.
Although the studies showed a small higher risk of heart problems with Pradaxa than with warfarin, the benefits of Pradaxa were still considered to outweigh its risks. If you take PRADAXA and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots.
Pradaxa should be stopped before elective surgery. Concomitant administration of P-gp inducers is expected to result in decreased dabigatran plasma concentrations, and should be avoided see sections dabigatra.
If treatment is not started on the day of surgery then treatment should be initiated with danigatran capsules once daily. After removal dabigattan a catheter, an interval of at least 2 hours should elapse before the administration of the first dose of Pradaxa. Summary of the safety profile In actively controlled VTE prevention trials 6, patients were treated with mg or mg Pradaxa daily. Please enter a valid email address Please enter a valid email address.
In general, it can be assumed that these measures of anti-coagulant activity may reflect dabigatran levels and can provide dabigatarn for the assessment of bleeding risk, i. Dabigatran etexilate was given twice daily over 3 consecutive days, on the 3 rd day either with or without cabigatran. Other referenced trademarks are owned by third parties.
Known bleeding complications such as compartment syndrome and acute renal failure due to hypoperfusion have been reported for Pradaxa.
There are limited efficacy and safety data for Pradaxa available in these patients and therefore they should be treated with caution. The capsules should be swallowed whole with water. These clots, which include deep vein thrombosis DVTcan be dangerous if they move to another part of the body such as the lungs. Each hard capsule contains 75 mg of dabigatran etexilate as mesilate.
Dose reductions are recommended for patients who receive concomitantly verapamil see table 1 above and sections 4. Transporter interactions P-gp inhibitors Concomitant use contraindicated see section 4.
For the full list of excipients, see section 6. P-gp inducers Concomitant use should be avoided. Pradaxa should only be given if the benefit outweighs bleeding risks.
Plasma concentrations of dabigatran showed a biexponential decline with a mean terminal half-life of 11 hours in healthy elderly subjects.
dbigatran Available in over 3, hospitals nationwide. The dabigatran AUC and C max were increased by about 1. For the prevention of stroke and blood clots in patients with non-valvular atrial fibrillation, Pradaxa is taken as one mg capsule twice a day and should be taken long term. Patients should be instructed to contact the treating physician if they develop gastrointestinal symptoms such as dyspepsia see section 4.
Subjects randomized to mg Pradaxa twice daily had a significantly higher risk for major GI bleeds compared with warfarin hazard ratio 1. Biotransformation Metabolism and excretion of dabigatran were studied following a single intravenous dose of radiolabeled dabigatran in healthy male subjects.
Although Pradaxa does not in general require routine anticoagulant monitoring, the measurement of dabigatran related anticoagulation may be helpful to detect excessive high exposure to dabigatran in the presence spd additional risk factors. Excessive anticoagulation may require interruption of Pradaxa treatment.